The LIAT1 Knockout HeLa Polyclonal Cells product provides a heterogeneous population of HeLa cells with CRISPR/Cas9-mediated disruption of the LIAT1 gene, encoding a long intergenic non-coding RNA (lncRNA). This polyclonal knockout cell population serves as a robust loss-of-function model for investigating LIAT1 function without the biases associated with single-cell cloning.
The host HeLa cell line is derived from a human cervical adenocarcinoma and is positive for human papillomavirus type 18 (HPV18). The viral oncoproteins E6 and E7 inactivate the tumor suppressors p53 and pRb, respectively, endowing HeLa cells with an immortalized phenotype and making them a widely used model for HPV-related cervical cancer and general cell biology research.
LIAT1 acts as a competing endogenous RNA (ceRNA) that sponges specific microRNAs, including miR-21 and miR-155, thereby derepressing the expression of their mRNA targets such as BCL2 and CCND1. This mechanism promotes cell proliferation and survival by enhancing PI3K/AKT and MAPK/ERK signaling pathways, with downstream effectors including AKT, mTOR, and cyclin D1. LIAT1 is transcriptionally regulated by MYC, p53, and NF-??B, and it interacts with the PRC2 complex (via EZH2 and SUZ12) and the RNA-binding protein HuR, integrating epigenetic and post-transcriptional regulatory networks. Consequently, LIAT1 modulates apoptosis and cell cycle progression, directly impacting BAX/BCL2 balance and cyclin D1 expression.
In HeLa cells, LIAT1 contributes to oncogenic phenotypes by maintaining proliferation and resistance to apoptosis. Disruption of LIAT1 in this polyclonal knockout population is expected to attenuate these processes, providing a physiologically relevant context for studying lncRNA-mediated regulation in a cervical cancer background. The HPV-driven inactivation of p53 and pRb creates a unique environment where LIAT1??s ceRNA function may be particularly critical for sustaining malignant growth, making this knockout model valuable for dissecting lncRNA dependencies in HPV-associated malignancies.
This polyclonal knockout cell product is suited for a broad range of functional assays, including RT-qPCR and RNA-seq for transcriptomic profiling, ChIRP for lncRNA-chromatin interactions, dual-luciferase reporter assays for miRNA target validation, and phenotypic analyses such as MTT, colony formation, and flow cytometry-based apoptosis detection. By enabling loss-of-function studies, it supports research into the ceRNA hypothesis, lncRNA biology in cervical cancer, and the identification of therapeutic targets within lncRNA signaling networks. For additional details and ordering, please contact Ascent Research.
